Catalog No.
DHD95101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Human epididymis-specific protein 5, CDW52, CAMPATH-1 antigen, Cambridge pathology 1 antigen, He5, HE5, Epididymal secretory protein E5, CD52, CDw52
Concentration
1.03 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P31358
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Campath-1H, LDP-03, CAS: 216503-57-0
Clone ID
Alemtuzumab
Alemtuzumab for the treatment of multiple sclerosis, PMID: 29309202
Alemtuzumab as Treatment for Multiple Sclerosis, PMID: 29500306
[Alemtuzumab therapy 2017], PMID: 29870645
Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis, PMID: 30144037
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis, PMID: 32503344
Alemtuzumab for Multiple Sclerosis, PMID: 27485945
A case of anaphylaxis to alemtuzumab, PMID: 30715557
Acquired haemophilia A after alemtuzumab therapy, PMID: 32700327
New cases of vasculitis after alemtuzumab, PMID: 32081067
Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review, PMID: 29352515
Alemtuzumab and prescription medication use in the MS population, PMID: 32403069
Alemtuzumab for multiple sclerosis, PMID: 27082500
Alemtuzumab therapy for multiple sclerosis, PMID: 23184314
Alemtuzumab, PMID: 18165760
Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts, PMID: 27882532
Alemtuzumab-associated diffuse alveolar damage - a case report, PMID: 32967641
Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations, PMID: 27799738
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF, PMID: 31826986
Anemia and sarcoidosis following treatment with alemtuzumab, PMID: 32979730
Alemtuzumab: Rare serious adverse events of a high-efficacy drug, PMID: 32298205
Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients, PMID: 31035777
Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ, PMID: 30307361
Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis, PMID: 29178444
Clinical observation during alemtuzumab administration, PMID: 32172992
Intracerebral haemorrhage during alemtuzumab administration, PMID: 30777657
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection, PMID: 32719676
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review, PMID: 30851640
Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients, PMID: 23187050
A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab, PMID: 30238817
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years, PMID: 33476880
Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis, PMID: 22660659
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management, PMID: 30785358
Listeria infection after treatment with alemtuzumab: a case report and literature review. Would antibiotic prophylaxis be considered?, PMID: 32487792
Alemtuzumab: the advantages and challenges of a novel therapy in MS, PMID: 24920854
Alemtuzumab to be restricted pending review, says EMA, PMID: 31034363
Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients, PMID: 30849681
Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation, PMID: 33037919
B and T cell prolymphocytic leukaemia, PMID: 31585622
Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: A case report, PMID: 32446212
Emerging safety issues in alemtuzumab-treated MS patients, PMID: 31368417
Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres, PMID: 32547557
Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study, PMID: 32890079
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis, PMID: 29848085
Kidney transplantation using alemtuzumab, belatacept, and sirolimus: Five-year follow-up, PMID: 32515087
Alemtuzumab depletion failure can occur in multiple sclerosis, PMID: 29247512
Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?, PMID: 26536426
The role of alemtuzumab in nonmyeloablative hematopoietic transplantation, PMID: 16720202
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations, PMID: 29525836
Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment, PMID: 31214176
Overview of alemtuzumab therapy for the treatment of T-cell lymphomas, PMID: 21980956
For research use only. Not for human or drug use.
